INSAID variant classification and Eurofever criteria guide optimal treatment strategy in patients with TRAPS: data from the Eurofever Registry

Key Findings

• ●226 patients classified by INSAID: Group A (pathogenic) 56%, Group B (uncertain) 35%, Group C (benign) 9%
• ●Anti-IL-1 drugs achieved >85% complete response in patients meeting Eurofever criteria
• ●No patients on anti-IL-1 treatment developed AA amyloidosis
• ●16% of Group A patients developed AA amyloidosis

Referenced in (1 disease)